The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer

Clinical Cancer Research

Volumn 13, Issue 2 II, 2007, Pages

  Cho, Daniel ^a,d   Signoretti, Sabina ^b,d   Regan, Meredith ^c,d   Mier, James W ^a,d   Atkins, Michael B ^a,d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d DANA FARBER HARVARD CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INTERFERON; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; SORAFENIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VATALANIB; VON HIPPEL LINDAU PROTEIN;

ADVANCED CANCER; ANEMIA; ASTHENIA; CANCER STAGING; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TOLERABILITY; GENE TARGETING; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; HYPOPHOSPHATEMIA; KIDNEY CARCINOMA; LIVER FUNCTION TEST; MACULOPAPULAR RASH; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; PATIENT SELECTION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ANOXIA; CARCINOMA, RENAL CELL; CLINICAL TRIALS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; INTERFERONS; KIDNEY NEOPLASMS; MODELS, BIOLOGICAL; PROTEIN KINASES; SIROLIMUS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33846866035     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1986     Document Type: Conference Paper

References (0)